Company intelligence / Profile preview

Therawisdom Biopharma Co., Ltd.

Unspecified, Shandong Sheng, Chinacenterwatch.com ↗

Ownership: Private
Development stage: Phase 1

Overview

TheraWisdom has at least one program in Phase I clinical trials targeting advanced malignancies. The trial TWP‑102 focuses on safety, tolerability, pharmacokinetics/dynamics, immunogenicity and preliminary efficacy in patients with advanced cancers. No published efficacy results yet.

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibodyFusion proteinBispecific antibody
Industry: Biotech

Drug pipeline

1 asset

TWP-101

Phase 1

Indications: Advanced solid tumors

Beyond the preview

Go deeper on Therawisdom Biopharma Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Therawisdom Biopharma Co., Ltd..

Explore the full profile